Analysed MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) News Sources
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
16-07-2026
proactiveinvestors.com
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
27-07-2026
yahoo.com
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
27-07-2026
proactiveinvestors.com
Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome
27-07-2026
yahoo.com
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
31-07-2026
yahoo.com
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
31-07-2026
yahoo.com
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
31-07-2026
proactiveinvestors.com
What is the current price of MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ)?
The current price of MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) is $0.4999.
MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) absolute price change since previous trading day?
The absolute price change of MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) since the previous trading day is $0.1899.
MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) percentage price change since previous trading day?
The percentage price change of MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) since the previous trading day is 61.2581%.
What is the most recent average sentiment score for MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ)?
The most recent average sentiment score for MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ)?
The most recent sentiment for MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ) is .
SEC-8K** Filing Available For MEDICUS PHARMA LTD -29 (MDCXW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.